Triple Treatment Reduces COPD Exacerbations |
Journal Updates
eMediNexus Coverage from: 
Triple Treatment Reduces COPD Exacerbations

0 Read Comments                

Inhaled triple therapy with budesonide, glycopyrrolate, and formoterol showed a signal of reducing all-cause mortality in patients with moderate to severe chronic obstructive pulmonary disease (COPD) at higher (320 μg) budesonide doses, suggest new findings from the large, multicenter, 52-week ETHOS trial.

Two doses of the glucocorticoid -- 160 μg and 320 μg -- were evaluated in the trial. The trial compared twice-daily doses of the triple therapy with dual treatment with glycopyrrolate and formoterol or formoterol and budesonide. Presenting the findings at an American Thoracic Society 2020 virtual session, Klaus Rabe, MD, of the Airway Research Center North in Grosshansdorf, Germany, revealed that at both budesonide doses, twice-daily treatment with the single inhaler triple therapy was associated with significantly lower rates of moderate to severe COPD exacerbations, compared with the dual treatments… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now